Chad Mineo: Platelet-Rich Plasma as an Adjunct to Rehabilitation in Grade 2 Hamstring Injuries
Chad Mineo, Physician Extender and Research Coordinator at Columbia University Irving Medical Center, shared a post on LinkedIn about a recent article by Clevio Desouza et al, adding:
“Platelet Rich Plasma (PRP) for Hamstrings:
High-quality ultrasound plus high-quality intervention equals better outcomes.
PRP hasn’t consistently beaten rehab for hamstring injuries—but context matters.
A 2025 RCT in European Journal of Orthopaedic Surgery and Traumatology showed:
US-guided PRP plus rehab equals faster RTP (approximately 26 versus approximately 34 days) plus improved early healing
Compare that to the negative British Journal of Sports Medicine (2015) trial:
- No imaging guidance
- Questionable PRP prep
- Broad patient selection
Not all PRP, or studies, are created equal.
Approach for grade 2 hamstrings:
- Rehab is the foundation (objective RTP criteria)
- PRP equals adjunct with uncertain upside
- Only if done right (image guidance, true PRP, structured rehab)
- Expect modest gains (days, not reinjury prevention)
Bottom line: PRP isn’t a magic bullet—but in the right hands, it may provide an edge.”
Title: Efficacy of platelet-rich plasma in grade 2 hamstring muscle injuries: results from a randomized controlled trial
Authors: Clevio Desouza, Vijay Shetty
Read the Full Article on Springer Nature.
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 5, 2026, 04:54Saneha Anjum Shaik: What Every Clinician Should Know Before Ordering Blood Tests
-
Jul 5, 2026, 04:37Mathis Richter: How The Bone Marrow Responds To Myocardial Infarction Predicts Clinical Outcome
-
Jul 5, 2026, 02:45Marie Luise Hütter-Krönke: Can a Short Course of BCMA-Targeted Therapy Induce Long-Term Remission in Refractory Autoimmune Disease?
-
Jul 5, 2026, 02:24Shreya Agarwa: Transforming Care For Adolescents With Heavy Menstrual Bleeding
-
Jul 4, 2026, 17:38Michael Stark: Greater Improvements in Cerebral Oxygenation With Restrictive Transfusion Thresholds
-
Jul 4, 2026, 17:27Reza Shojaei: How America Won the Plasma Race
-
Jul 4, 2026, 17:26Akshat Jain: The First CRISPR-Cas9 Gene Therapy Approved for Children as Young as 2 with SCD
-
Jul 4, 2026, 17:25Francesca Palandri: Dynamic, Treatment Response-Driven Risk Assessment in Polycythemia Vera
-
Jul 4, 2026, 17:24Thierry Burnouf: The Fragile Supply of Human Hyperimmune Immunoglobulins